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Large randomized controlled trials have demonstrated that cardiac
resynchronization therapy (CRT) improves morbidity and mor-
tality in patients with moderate to severe heart failure
[New York Heart Association (NYHA) functional class III– IV],
reduced left ventricular ejection fraction (LVEF 35%), and a
broad QRS complex .120 ms on optimal medical therapy.1 –3
As a result, the impressive survival benefit as well as the improve-
ment in heart failure symptoms and quality of life observed in these
trials have spurred interest in extending resynchronization therapy
to a larger number of heart failure patients. Indeed, several lines of
evidence indicate that currently employed guidelines (mainly based
on the selection criteria used in the aforementioned pivotal trials)
may not be perfect at identifying patients most likely to benefit
from CRT, with a significant proportion of patients being ‘non-
responders’ based on clinical outcomes or echocardiographic
remodelling.4 Conversely, results from various small studies
imply that certain patient populations may benefit from CRT
despite the fact that they do not fulfil the criteria of current
CRT guidelines.5– 7 In the absence of randomized trials, data
from large-scale ‘real world’ surveys provide a unique opportunity
to study both the current practice regarding the employment of
a novel type of therapy as well as its efficacy and safety, including
‘off-label’ indications.
The European CRT Survey, a joint initiative by the Heart Failure
Association (HFA) and the European Heart Rhythm Association
(EHRA) of the European Society of Cardiology (ESC), reports on
the current European practice in the use of CRT.8 In order to
provide this information, 2438 patients from 141 centres in 13
European countries who underwent successful implantation of a
CRT device were followed from November 2008 until June 2009. In
addition to providing a detailed description of patient demographics,
selection criteria, and periprocedural outcomes, the survey’s data
were further dissected according to the implanted device and age
of the recipients. The authors found that patients receiving CRT-P
[i.e. a biventricular pacing device without implantable cardiover-
ter–defibrillator (ICD) function] were older, less likely to present
with co-morbidities including ischaemic heart disease or diabetes
mellitus, and had better left ventricular function as compared with
those receiving a CRT-D (i.e. CRT þ ICD) device. Furthermore,
the data demonstrate that patients older than 75 years more fre-
quently had atrial fibrillation, a longer QRS duration, or concomitant
co-morbidities (as reflected by higher serum creatinine and B-type
natriuretic peptide (BNP) levels] as compared with those younger
than 75 years. Probably as a result of the latter (and possibly for
socioeconomic reasons), older patients were more likely to
receive CRT-P devices.
While most of these associations do not necessarily come as a sur-
prise and are in good agreement with previous trials and clinical
experience, the survey does also show some interesting aspects of
cardiac resynchronization practice across Europe which deserve
further attention. Most interestingly, a substantial number of patients
received CRT devices for ‘off-label’ indications, including 9% of
patients with a narrow QRS complex (,120 ms) as well as 10%
with a QRS duration between 120 and 129 ms. Currently available
data regarding the benefit of CRT in heart failure patients with a
narrow QRS complex are conflicting. Using echocardiography-
based dyssynchrony criteria, several small single-centre studies
were able to identify patients with a narrow QRS who responded
favourably to CRT.5,6,9 In contrast, the results of two recent random-
ized pilot studies (RethinQ10 and ESTEEM-CRT) remained elusive
due to several inherent limitations.11 Eventually, the answer to
whether CRT improves morbidity and mortality in this particular
patient group can only be provided by an adequately powered,
endpoint-driven randomized clinical trial, which is currently
underway (Echocardiography Guided Cardiac Resynchronization
Therapy—EchoCRT; NCT00683696, www.clinicaltrials.gov).11
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Before the results of this trial become available, it will be of interest
to observe the direction in which the expected 1 year data from
the survey by Dickstein et al.8 will be pointing. Unfortunately,
only qualitative assessment instead of quantitative (echocardio-
graphic) parameters of left ventricular dyssynchrony were regis-
tered for these patients, which will make further comprehensive
analysis of this subgroup’s outcome difficult.
Previous small trials have, moreover, indicated that patients with
atrial fibrillation may profit from CRT,7 but evidence from large
trials is lacking as this particular patient group was generally
excluded. Controversy currently exists, however, regarding the
necessity of AV nodal ablation, of ablation of atrial fibrillation
itself, concomitant rate- or rhythm-controlling medication, and
optimal device programming. In the survey by Dickstein et al., 8
23% of patients implanted were in atrial fibrillation. In view of
the large proportion of heart failure patients with atrial fibrillation
in clinical practice and the fact that data from large trials are scarce,
further information on these parameters would have been desir-
able for this interesting subgroup. Nevertheless, outcome data
after 1 year (possibly including this interesting information) will
demonstrate to what extent these patients benefit in terms of
clinical and echocardiographic improvement.
Evidence is emerging that patients with mildly symptomatic
heart failure (i.e. NYHA class ,III) may also benefit from CRT.
Indeed, data from the REVERSE trial,12 especially after 24
months of CRT (presented at the Annual meeting of the American
College of Cardiology 2009 in Orlando) as well as preliminary
results from MADIT-CRT (communicated by Boston Scientific in
June 2009 and scheduled to be presented at the ESC 2009), indi-
cate that CRT improves morbidity and mortality even in patients
with NYHA class I– II heart failure. In the survey, 2 and 20% of
the patients enrolled were indeed in NYHA functional class I
and II, respectively. So far, however, the National Institute for
Health and Clinical Excellence (NICE) has indicated that such
patients may only be candidates for CRT if clinical deterioration
has recently occurred. While in the overall survey population
57% of patients are reported to have been hospitalized for heart
failure during the last year, no data are given regarding a recent
deterioration in the subgroup of mildly symptomatic patients.
Hence, a substantial proportion of these patients may have under-
gone CRT implantation on an off-label basis. In light of the above-
mentioned recent study results, this intuitive expansion of an effec-
tive therapy above and beyond current guidelines seems to have
been a very reasonable choice. Follow-up data of the survey will
show whether a similar response rate will also be observed in
this ‘real world’ population.
In addition to patient demographics and selection criteria, the
authors also present periprocedural outcome data after implan-
tation of CRT devices. In terms of efficacy, the majority of patients
improved clinically, as demonstrated by a lower NYHA class after
CRT implantation. Electrocardiographically, the average QRS dur-
ation decreased significantly with biventricular pacing; no acute
changes in echocardiographic parameters are reported. From a
safety point of view, the reported perioperative complication
rate was low, which may reflect the implanting physicians’ experi-
ence and skill over time. It may also be due to the fact, however,
that only successful implantations were allowed to be enrolled in
the survey; indeed, the numbers of CRT-eligible patients who
failed or did not undergo implantation are not reported. The
lack of stringent registration and subsequent analysis of all consecu-
tively screened patients in whom CRT implantation was attempted
unfortunately reduces the survey’s validity in assessing the safety of
CRT implantation in the survey population.
All of this notwithstanding, the survey by Dickstein et al.8 gives a
nice and robust overview of the current practice regarding CRT
across a wide range of European centres. Planned assessment of
survey patients after 1 year, including data on morbidity and mortality
as well as echocardiographic remodelling and arrhythmias, will be
eagerly awaited to evaluate the efficacy of CRT in this real world
population. In view of the substantial number of patients treated
with CRT for off-label indications, this will also be of interest from a
socioeconomic point of view. From a scientific perspective, further
information on less well studied subpopulations (including patients
with atrial fibrillation, mildly symptomatic subjects, and patients
with a narrow QRS complex, see Figure 1) as well as more in-depth
information on technical subtleties such as left ventricular lead
location, device programming, and optimization would be desirable.
Importantly, consecutive patient enrolment and registration, as well
as critical evaluation of unsuccessful CRT implantation will be
crucial in order to assess the safety of CRT in the study population.
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Figure 1 Patient selection for CRT—present and future.
Current indications for CRT according to current European
Society of Cardiology (ESC)/European Heart Rhythm Association
(EHRA) guidelines13 as well as potential future candidates
for CRT are shown. See text for details. CHF, congestive
heart failure; LVEF, left ventricular ejection fraction; NYHA,
New York Heart Association.
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Gu¨nter Breithardt, FESC, FACC, FHRS, recently retired
after a long and illustrious career in Cardiology from
The Westfa¨lische-Wilhelms-University Hospital Mu¨nster,
Germany, and, Director, Department of Molecular
Cardiology The Leibniz-Institute
Dr Breithardt was first made a full Professor of Medicine (Cardiology) in 1982 at Du¨sseldorf University,
Germany where he was also Director of the Electrophysiology Labs, and has been at the forefront of
clinical electrophysiology from the early 1970s:
amongst the leading investigators of sinus node function,
a pioneer of signal-averaged electrocardiography,
developed a large programme for electrophysiologic mapping, including intraoperative management of tachycardias.
In 1984, his group implanted the first ICDs in Germany, and in 1989 were the first to implant 3rd generation ICDs world-wide.
In 1986 they were the first to use radio-frequency ablation for arrhythmias.
He established and led a comprehensive research programme at Mu¨nster focussing on arrhythmias and heart failure mechanisms
encompassing molecular genetics. His group was involved in the consortium that identified the first gene mutations for Brugada’s syn-
drome; they described the first mutation responsible for sinus node disease, and identified plakophilin-2 as the most prevalent mutation
underlying arrhythmogenic right ventricular cardiomyopathy.
Dr Breithardt served the ESC in various positions:
1980–1984, Secretary General of the 1984 ESC Congress,
1986–2000, initially an ex-officio ESC Board member as its first Scientific Programme chair,
1996–1998, ESC President.
He was the first chairman of the ESC Research Committee, and established what is now the ESC Practice Guideline Committee, and
chaired the ESC Working Group on Arrhythmias.
In 1990, he chaired the first-ever joint Task Force between the ESC, AHA, and ACC on Standards for Analysis of Ventricular Late
Potentials Using High-Resolution or Signal-Averaged Electrocardiography.
As first chairman of the 1998 annual ESC Congress Programme Committee, he developed a working relationship with the pro-
gramme committee chair of the AHA.
1987–1988 he was the European member on Executive Board of World Heart Federation.
1999–2001 President, German Cardiology Society.
His main interest as a clinical scientist now is the genetic background of rare cardiac arrhythmic diseases and their clinical presen-
tation, arrhythmias, heart failure and sudden cardiac death.
Away from medicine, he loves outdoor activities particularly enjoying Northern Norway (his wife’s homeland), where he hikes,
bicycles, sails, and goes fishing and cross-country skiing. Their two children decided independently to enter medicine: their son is
now an academic cardiologist and their daughter, a veterinarian, is interested in heart disease of pets and domestic animals.
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